Our goal:
Each year, millions suffer from cardiac arrest and hundreds of thousand of children suffer from neonatal asphyxia (lack of oxygen at birth). To minimise the harm from this, external or internal cooling is used, activating the mild hypothermia response, a detailed and highly regulated process in the body . Our goal is to understand the genetic background of this response in detail an develop medications to manipulate it.
Our Institutions and investors
All
-
Kaldur recognized as a national healthtech leader
The Nelson advisors consulting firm just released its list of twenty future leaders within Icelandic healthtech and medtech – and Kaldur is number 7 – we are grateful for the recognition! https://www.healthcare.digital/single-post/20-future-icelandic-healthtech-and-medtech-leaders
-
Dr. Björnsson receives grant of excellence
Dr. Björnssons lab at the University of Iceland has just received a grant of excellence (öndvegisstyrkur) from Rannis, the Icelandic Research Fund. The grant is for 60 million ISK (500 thousand USD) per year for 3 years. The grant will be used to further understand the molecular mechanism of hypothermia.
-
Funding by Kría
On December 3rd 2025 it was announced that KALDUR therapeutics had obtained a funding offer from Kría – The New Business Venture Fund. The funding offer followed a funding round where 88 companies applied for funding and 22 were invited for further discussion, from which 11 were choosen for funding offer. The offer is contingent…
KALDUR Therapeutics 